Novocure Ltd
Open
SectorGezondheidszorg
17.52 -1.46
Overzicht
Wijziging aandelenprijs
24u
Min
17.43
Max
18.27
Inkomsten | -47M -71M |
|---|---|
Verkoop | -295K 174M |
EPS | -0.62 |
Winstmarge | -40.871 |
Werknemers | 1,605 |
EBITDA | -29M -63M |
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | +46.23% upside |
Volgende Winsten | 23 jul 2026 |
|---|
Marktkapitalisatie | 506M 2B |
|---|---|
Vorige openingsprijs | 18.98 |
Vorige sluitingsprijs | 17.52 |
Nieuwssentiment
By Acuity
50%
50%
146 / 342 Rangschikking in Healthcare
Novocure Ltd Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.